1. Home
  2. MDJH vs AYTU Comparison

MDJH vs AYTU Comparison

Compare MDJH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDJH
  • AYTU
  • Stock Information
  • Founded
  • MDJH 2002
  • AYTU N/A
  • Country
  • MDJH United Kingdom
  • AYTU United States
  • Employees
  • MDJH N/A
  • AYTU N/A
  • Industry
  • MDJH Real Estate
  • AYTU Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDJH Finance
  • AYTU Health Care
  • Exchange
  • MDJH Nasdaq
  • AYTU Nasdaq
  • Market Cap
  • MDJH 13.6M
  • AYTU 15.0M
  • IPO Year
  • MDJH 2019
  • AYTU N/A
  • Fundamental
  • Price
  • MDJH $0.61
  • AYTU $2.25
  • Analyst Decision
  • MDJH
  • AYTU
  • Analyst Count
  • MDJH 0
  • AYTU 0
  • Target Price
  • MDJH N/A
  • AYTU N/A
  • AVG Volume (30 Days)
  • MDJH 46.6K
  • AYTU 31.2K
  • Earning Date
  • MDJH 01-01-0001
  • AYTU 11-12-2024
  • Dividend Yield
  • MDJH N/A
  • AYTU N/A
  • EPS Growth
  • MDJH N/A
  • AYTU N/A
  • EPS
  • MDJH N/A
  • AYTU N/A
  • Revenue
  • MDJH $114,849.00
  • AYTU $81,002,000.00
  • Revenue This Year
  • MDJH N/A
  • AYTU N/A
  • Revenue Next Year
  • MDJH N/A
  • AYTU N/A
  • P/E Ratio
  • MDJH N/A
  • AYTU N/A
  • Revenue Growth
  • MDJH 289.97
  • AYTU N/A
  • 52 Week Low
  • MDJH $0.59
  • AYTU $2.16
  • 52 Week High
  • MDJH $2.19
  • AYTU $3.50
  • Technical
  • Relative Strength Index (RSI)
  • MDJH 31.54
  • AYTU 39.00
  • Support Level
  • MDJH $0.62
  • AYTU $2.26
  • Resistance Level
  • MDJH $0.68
  • AYTU $2.44
  • Average True Range (ATR)
  • MDJH 0.05
  • AYTU 0.14
  • MACD
  • MDJH 0.01
  • AYTU -0.02
  • Stochastic Oscillator
  • MDJH 4.01
  • AYTU 2.03

About MDJH MDJM LTD

MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, as well as real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

Share on Social Networks: